

1 August 2023

**Oncimmune Holdings plc**  
("Oncimmune" or the "Company")

**Changes to the Board**

Oncimmune Holdings plc (AIM: ONC.L), the leading autoantibody profiling company to the pharmaceutical and biotechnology industry, is pleased to announce that Martin Gouldstone has today started as the Company's new Chief Executive Officer and joined the Board of Directors.

With Martin as Chief Executive Officer, Ron Kirschner, who was appointed as acting Chief Executive Officer in June, will be taking up the role of Chief Operating Officer and has stepped down from the Board. Ron remains Oncimmune's Company Secretary.

Regulatory disclosures in relation to Martin Gouldstone's appointment, as required under Schedule 2(g) of the AIM Rules for Companies, were contained in the Company's announcement on 12 July 2023 and have not changed as at the date of this announcement.

**For further information:**  
**Oncimmune Holdings plc**  
[contact@oncimmune.co.uk](mailto:contact@oncimmune.co.uk)

**Singer Capital Markets (Nominated Adviser and Broker)**  
Phil Davies, Harry Gooden, George Tzimas, James Fischer  
+44 (0)20 7496 3000

**Zeus (Joint Broker)**  
Dominic King, Victoria Ayton, Dan Bate  
+44 (0)20 3829 5000  
+44 (0)20 3727 1000

**About Oncimmune**

Oncimmune is a specialist pharmaceutical services company, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a contract discovery and development service business whose ImmunoINSIGHTS platform delivers actionable insights into therapies to the Company's pharmaceutical and biotech partners.

Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients. Oncimmune's ImmunoINSIGHTS service business at its discovery research centre in Dortmund, Germany. The ImmunoINSIGHTS business development team are based in the US and Europe.

For more information, visit [www.oncimmune.com](http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOASDEFFFESEIW